Literature DB >> 19246978

Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly.

S Grottoli1, V Gasco, A Mainolfi, G Beccuti, G Corneli, G Aimaretti, C Dieguez, F Casanueva, E Ghigo.   

Abstract

Starvation exerts critical influence on somatotroph and leptin secretion. Fasting enhances GH levels in normal subjects, but not in GH hyposecretory states, while it always inhibits leptin secretion. We aimed to clarify the GH/IGF-I and metabolic response to short-term fasting in a GH hypersecretory state such as acromegaly. To this goal, in 8 active acromegalic (ACRO) and in 7 normal women (NS) we evaluated mean GH (mGHc), leptin (mLEPc), insulin (mINSc), glucose (mGLUc) concentrations as well as IGF-I, IGF binding protein (IGFBP)-3, IGFBP-1, and free fatty acid (FFA) levels before and after 36-h fasting. Before fasting, mGHc, IGF-I, mINSc, mGLUc, and FFA levels in ACRO were higher (p<0.01) than in NS. IGFBP-3, IGFBP-1, and mLEPc were similar in ACRO and in NS. Fasting clearly (p<0.02) increased mGHc in NS only. After 36-h fasting, significant IGF-I reduction was recorded in NS only (p<0.03). IGFBP-3 did not change both in ACRO and NS. IGFBP-1 significantly increased (p<0.05) after fasting in both groups but in ACRO were lower (p<0.03) than in NS. Fasting decreased (p<0.03) mLEPc, mGLUc, and mINSc in ACRO as well as in NS; mINSc and mGLUc after fasting in ACRO persisted higher (p<0.005) than in NS. FFA levels were increased by fasting in NS (p<0.02), but not in ACRO. This study shows that GH/IGF-I axis, glucose metabolism, and lypolisis but not leptin display some degree of refractoriness to short-term fasting in acromegaly. The lack of any GH response to fasting in acromegaly would likely reflect neuroendocrine alterations secondary to the GH hypersecretory state. On the other hand, the lack of somatotropic response and the peculiarly blunted metabolic reaction to short-term fasting would partially reflect the delayed adaptation of insulin resistance to starvation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19246978     DOI: 10.1007/bf03345660

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  43 in total

1.  Role of growth hormone (GH)-releasing hormone and somatostatin on leptin-induced GH secretion.

Authors:  E Carro; R M Señarís; L M Seoane; L A Frohman; A Arimura; F F Casanueva; C Diéguez
Journal:  Neuroendocrinology       Date:  1999-01       Impact factor: 4.914

Review 2.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

3.  The in vitro effect of leptin on basal and growth hormone-releasing hormone-stimulated growth hormone secretion from the ovine pituitary gland.

Authors:  S Roh; I J Clarke; R Xu; J W Goding; K Loneragan; C Chen
Journal:  Neuroendocrinology       Date:  1998-12       Impact factor: 4.914

4.  Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution.

Authors:  C T Montague; J B Prins; L Sanders; J E Digby; S O'Rahilly
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

5.  Changes of serum leptin and endocrine and metabolic parameters after 7 days of energy restriction in men and women.

Authors:  G R Dubuc; S D Phinney; J S Stern; P J Havel
Journal:  Metabolism       Date:  1998-04       Impact factor: 8.694

Review 6.  Clinical review 94: What's in a name? In search of leptin's physiologic role.

Authors:  J S Flier
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 7.  Clinical review 90: Leptin and clinical medicine: a new piece in the puzzle of obesity.

Authors:  G A Bray; D A York
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

8.  Plasma sex hormones are significantly associated with plasma leptin concentration in healthy subjects.

Authors:  G Paolisso; M R Rizzo; C M Mone; M R Tagliamonte; A Gambardella; M Riondino; C Carella; M Varricchio; F D'Onofrio
Journal:  Clin Endocrinol (Oxf)       Date:  1998-03       Impact factor: 3.478

9.  Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.

Authors:  M Maccario; M Procopio; S Grottoli; S E Oleandri; G M Boffano; M Taliano; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1996-03       Impact factor: 8.694

10.  Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.

Authors:  T Shibasaki; M Hotta; A Masuda; T Imaki; N Obara; N Hizuka; K Takano; I Wakabayashi; H Demura; N Ling
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

View more
  4 in total

1.  Comparison of colonoscopy and fecal occult blood testing as a first-line screening of colonic lesions in patients with newly diagnosed acromegaly.

Authors:  F Bogazzi; M Lombardi; I Scattina; C Urbani; E Marciano; A Costa; P Pepe; G Rossi; E Martino
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

Review 2.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 3.  Determinants of GH resistance in malnutrition.

Authors:  Pouneh K Fazeli; Anne Klibanski
Journal:  J Endocrinol       Date:  2014-01-27       Impact factor: 4.286

Review 4.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.